Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
Clinical trial NCT04142619 · TERMINATED
Trial details
- NCT number
- NCT04142619
- Sponsor
- Cellectis S.A.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-21
- Primary completion
- 2023-06-18
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.